المؤلفون: Fareeda Hosein, Veerle de Pril, Jon M. Richards, Jean-Jacques Grob, Vanna Chiarion-Sileni, Henrik Schmidt, Virginia Ferraresi, Alessandro Testori, Omid Hamid, Jeffrey S. Weber, Jedd D. Wolchok, Alexander M.M. Eggermont, Paolo A. Ascierto, Stefan Suciu, Caroline Robert, Michael Smylie, Reinhard Dummer, Michal Kicinski, Céleste Lebbé, Michele Maio

المساهمون: University of Zurich, Eggermont, Alexander M M

المصدر: Eggermont, A M M, Chiarion-Sileni, V, Grob, J J, Dummer, R, Wolchok, J D, Schmidt, H, Hamid, O, Robert, C, Ascierto, P A, Richards, J M, Lebbe, C, Ferraresi, V, Smylie, M, Weber, J S, Maio, M, Hosein, F, de Pril, V, Kicinski, M, Suciu, S & Testori, A 2019, ' Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma : long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial ', European Journal of Cancer, vol. 119, pp. 1-10 . https://doi.org/10.1016/j.ejca.2019.07.001Test

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Skin Neoplasms, 610 Medicine & health, Ipilimumab, Kaplan-Meier Estimate, Placebo, Adjuvant therapy, Metastasis, Long-term results, Melanoma, Phase III trial, Stage III, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Double-Blind Method, Internal medicine, medicine, Humans, 1306 Cancer Research, Aged, Aged, 80 and over, business.industry, Hazard ratio, 10177 Dermatology Clinic, Cancer, Middle Aged, Prognosis, medicine.disease, Discontinuation, 030104 developmental biology, Chemotherapy, Adjuvant, Lymphatic Metastasis, 030220 oncology & carcinogenesis, Female, 2730 Oncology, business, Follow-Up Studies, medicine.drug

وصف الملف: 806_Eggermont_A._et_al._Adjuvant_ipilimumab_versus_placebo_after_complete_resection_of_stage_III_melanoma_etc._EJC_2019.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::211084f57afa1977a4f55abb0eae48ceTest
https://doi.org/10.1016/j.ejca.2019.07.001Test

المؤلفون: Abdel Saci, Akintunde Bello, Rui Wang, Megan Wind-Rotolo, Max Qian, Yan Feng, Fareeda Hosein, Jasmine I. Rizzo, Junying Zheng, Xiao Shao, Amit Roy, Rebecca A. Moss, Irene Pak

المصدر: Cancer Research. 79:2273-2273

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, Randomization, Receiver operating characteristic, business.industry, medicine.medical_treatment, Melanoma, Dacarbazine, Area under the curve, Cancer, medicine.disease, Machine learning, computer.software_genre, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Cytokine, Oncology, 030220 oncology & carcinogenesis, medicine, Artificial intelligence, Nivolumab, business, computer, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::e31eeecc9acb24aaec93fe68e9f6ec7eTest
https://doi.org/10.1158/1538-7445.am2019-2273Test